CNR1 and Parkinson disease: Some studies have shown that CB1R expression is reduced in the basal ganglia of PD patients, that the upregulation of CB1R activity may contribute to the pathological process and worsen the disease, and that the use of CB1R antagonists alleviates motor symptoms in PD models [63,75].